Rejuvant™ Safety and Biomarker Study
M
Malaz Boustani, MD
Primary Investigator
Not Recruiting
45 years - 65 years
All
Phase
3
1 Location
Brief description of study
This is a study to evaluate the effect of taking RejuvantTM on C-reactive protein (CRP, an inflammatory marker) and collect safety data on participants, who will take either RejuvantTM or a placebo for 9 months.
RejuvantTM is a dietary supplement.
Detailed description of study
If you are eligible to take part in the study, you will visit the clinic 4 times over the course of the study. You will also respond to a telephone questionnaire each month you do not come to the clinic. Your vital signs will be recorded. Your blood will be drawn for laboratory tests, and your saliva will be collected for a specific DNA methylation test, done to determine biological age.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: healthy,postmenopausal,1908473792
-
Age: 45 years - 65 years
-
Gender: All
Eligibility Criteria
Men between the ages of 45-65
Postmenopausal women up to age 65 (women must not have had a menstrual period for at least 1 year)
Exclusion Criteria
Diabetes for which you must take medication
Severe mental illness
Congestive heart disease or had a heart attack within the past year
Cancer diagnosis in the past 5 years
Obesity or anorexia
Hospitalization in the past 12 months
Current smoker
Additional Information:Participants will receive a $40 gift card for each completed clinic visit for up to a total of $160 in gift cards for completing all study procedures.
Updated on
01 Aug 2024.
Study ID: 1908473792
